SEARCH

SEARCH BY CITATION

Reference

  • 1
    Moradpour D, Wands JR. The molecular pathogenesis of hepatocellular carcinoma. J Viral Hepat 1994; 1: 1731.
  • 2
    Ozturk M. Genetics aspects of hepatocellular carcinogenesis. Semin Liver Dis 1999; 19: 235242.
  • 3
    Michalopoulos GK, DeFrances MC. Liver regeneration. Science 1997; 276: 6066.
  • 4
    Scharf JG, Schmidt-Sandte W, Pahernik SA, Ramadori G, Braulke T, Hartmann H. Characterization of the insulin-like growth factor axis in a human hepatoma cell line (PLC). Carcinogenesis 1998; 19: 21212128.
  • 5
    Tanaka S, Sugimachi K, Maehara S, Harimoto N, Shirabe K, Wands JR, Sugimachi K. Oncogenic signal transduction and therapeutic strategy for hepatocellular carcinoma. Surgery 2002; 131: S142S147.
  • 6
    Chen RH, Su YH, Chuang RLC, Chang TY. Suppression of transforming growth factor-β-induced apoptosis through a phosphatidylinositol 3-kinase/Akt-dependent pathway. Oncogene 1998; 17: 19591968.
  • 7
    White MF. The IRS-signalling system: a network of docking proteins that mediate insulin action. Mol Cell Biochem 1998; 182: 311.
  • 8
    Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000; 21: 215244.
  • 9
    Scharf JG, Dombrowski F, Ramadori G. The IGF axis and hepatocarcinogenesis. J Clin Pathol 2001; 54: 138144.
  • 10
    Lin SB, Hsieh SH, Hsu HL, Lai MY, Kan LS, Au LC. Antisense oligode-oxynucleotides of IGF-II selectively inhibit growth of human hepatoma cells overproducing IGF-II. J Biochem 1997; 122: 717722.
  • 11
    Tanaka S, Wands JR. A carboxy-terminal truncated insulin receptor substrate-1 dominant negative protein reverses the human hepatocellular carcinoma malignant phenotype. J Clin Invest 1996; 98: 21002108.
  • 12
    Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its decovery. Biochem J 2001; 359: 116.
  • 13
    Harwood AJ. Regulation of GSK-3: a cellular multiprocessor. Cell 2001; 105: 821824.
  • 14
    Cross DAE, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378: 785789.
  • 15
    van Weeren PC, de Bruyn KMT, de Vries-Smits AMM, van Lint J, Burgering BMT. Essential role for protein kinase B (PKB) in insulin-induced glycogen synthase kinase 3 inactivation. J Biol Chem 1998; 273: 1315013156.
  • 16
    Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P. Binding of GSK3β to the APC-β-catenin complex ánd regulation of complex assembly. Science 1996; 272: 10231026.
  • 17
    Yost C, Torres M, Miller JR, Huang E, Kimelman D, Moon RT. The axis-inducing activity, stability, and subcellular distribution of β-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev 1996; 10: 14431454.
  • 18
    Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998; 12: 34993511.
  • 19
    Nikolakaki E, Coffer PJ, Hemelsoet R, Woodgett JR, Defize LH. Glycogen synthase kinase 3 phosphorylates Jun family members in vitro and negatively regulates their transactivating potential in intact cells. Oncogene 1993; 8: 833840.
  • 20
    Lovestone S, Reynolds CH, Latimer D, Davis DR, Anderton BH, Gallo JM, Hanger D, et al. Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr Biol 1994; 4: 10771086.
  • 21
    Pap M, Cooper GM. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem 1998; 273: 1992919932.
  • 22
    Bijur GN, de Sarno P, Jope RS. Glycogen synthase kinase-3β facilitates staurosporine and heat shock-induced apoptosis. Protection by lithium. J Biol Chem 2000; 275: 75837590.
  • 23
    Hetman M, Cavanaugh JE, Kimelman D, Xia Z. Role of glycogen synthase kinase-3β in neuronal apoptosis induced by trophic withdrawal. J Neurosci 2000; 20: 25672574.
  • 24
    Lucas JL, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J. Decreased nuclear β-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3β conditional transgenic mice. EMBO J 2001; 20: 2739.
  • 25
    Nikoulina SE, Ciaraldi TP, Mudaliar S, Mohideen P, Carter L, Henry RR. Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. Diabetes 2000; 49: 263271.
  • 26
    Eldar-Finkelman H, Schreyer SA, Shinohara MM, Le Boeuf RC, Krebs EG. Increased glycogen synthase kinase-3 activity in diabetes- and obesityprone C57BL/6J mice. Diabetes 1999; 48: 16621666.
  • 27
    Lavoie L, Band CJ, Kong M, Bergeron JJM, Posner BI. Regulation of glycogen synthase in rat hepatocytes. J Biol Chem 1999; 274: 2827928285.
  • 28
    Park BC, Kido Y, Accili D. Differential signaling of insulin and IGF-1 receptors to glycogen synthesis in murine hepatocytes. Biochemistry 1999; 38: 75177523.
  • 29
    Syed NA, Khandelwal RL. Reciprocal regulation of glycogen phosphorylase and glycogen synthase by insulin involving phosphatidylinositol-3 kinase and protein phosphatase-1 in HepG2 cells. Mol Cell Biochem 2000; 211: 123136.
  • 30
    Lakehal F, Dansette PM, Becquemont L, Lasnier E, Delelo R, Balladur P, Poupon R, et al. Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes. Chem Res Toxicol 2001; 14: 694701.
  • 31
    Cariani E, Dubois N, Lasserre C, Briand P, Brechot C. Insulin-like growth factor II (IGF-II) mRNA expression during hepatocarcinogenesis in transgenic mice. J Hepatol 1991; 13: 220226.
  • 32
    Schirmacher P, Held WA, Yang D, Chisari FV, Rustum Y, Rogler CE. Reactivation of insulin-like growth factor II during hepatocarcinogenesis in transgenic mice suggests a role in malignant growth. Cancer Res 1992; 52: 25492556.
  • 33
    Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoël MJ, Bertrand F, Cherqui G, Perret C, Capeau J. Insulin and IGF-1 stimulate the β-catenin pathway through two signalling cascades involving GSK-3β inhibition and ras activation. Oncogene 2001; 20: 252259.
  • 34
    Auclair M, Vigouroux C, Desbois-Mouthon C, Deibener J, Kaminski, Lascols O, Cherqui G, et al. Antiinsulin receptor autoantibodies induce insulin receptors to constitutively associate with insulin receptor substrate-1 and-2 and cause severe cell resistance to both insulin and insulinlike growth factor 1. J Clin Endocrinol Metab 1999; 84: 31973206.
  • 35
    Smith U, Carvalho E, Mosialou E, Beguinot F, Formisano P, Rondinone C. PKB inhibition prevents the stimulatory effect of insulin on glucose transport and protein translocation but not on the antilipolytic effect in rat adipocytes. Biochem Biophys Res Commun 2000; 268: 315320.
  • 36
    Oriente F, Formisano P, Miele C, Fiory F, Maitan MA, Vigliotta G, Trencia A, et al. Insulin receptor substrate-2 phosphorylation is necessary for protein kinase C activation by insulin in L6hIR cells. J Biol Chem 2001; 276: 3710937119.
  • 37
    Tsujio I, Tanaka T, Kudo T, Nishikawa T, Shinozaki K, Grundke-Iqbal I, et al. Inactivation of glycogen synthase kinase-3 by protein kinase Cδ: implications for regulation of phosphorylation. FEBS Lett 2000; 469: 111117.
  • 38
    Ballou LM, Tian PY, Lin HY, Jiang YP, Lin RZ. Dual regulation of glycogen synthase kinase-3β by the α1A adrenergic receptor. J Biol Chem 2001; 276: 4091040916.
  • 39
    Standaert ML, Galloway L, Karnam P, Bandyopadhyay G, Mosca J, Farese RV. Protein kinase C- as a downstream effector of phosphatidylinositol 3-kinase during insulin stimulation in rat adipocytes. J Biol Chem 1997; 272: 3007530082.
  • 40
    He TC, Sparks AB, Rago, Hermeking, Zawel L, Da Costa LT, Morin PJ, et al. Identification of c-MYC as a target of the APC pathway. Science 1998; 281: 1509151512.
  • 41
    Martin DC, Fowlkes JL, Babic B, Khokha R. Insulin-like growth factor II signaling in neoplastic proliferation is blocked by transgenic expression of the metalloproteinase inhibitor TIMP-1. J Cell Biol 1999; 146: 881892.
  • 42
    Kawai HF, Kaneko S, Honda M, Shirota Y, Kobayashi K. α-fetoprotein-producing hepatoma cell lines share common expression profiles of genes in various categories demonstrated by cDNA microarray analysis. Hepatology 2001; 33: 676691.
  • 43
    Marotta A, Tan C, Gray V, Malik S, Gallinger S, Sanghera J, Dupuis B, et al. Dysregulation of integrin-linked kinase (ILK) signaling in colonic polyposis. Oncogene 2001; 20: 62506257.
  • 44
    Troussard AA, Tan C, Yoganathan N, Dedhar S. Cell-extracellular matrix interactions stimulate the AP-1 transcription factor in an integrin-linked kinase- and glycogen synthase kinase 3-dependent manner. Mol Cell Biol 1999; 19: 74207427.
  • 45
    Leung-Hagesteijn C, Mahendra A, Naruszewicz I, Hannigan GE. Modulation of integrin signal transduction by ILKAP, a protein phosphatase 2C associating with the integrin-linked kinase, ILK1. EMBO J 2001; 20: 21602170.
  • 46
    Toker A. Signaling through protein kinase C. Front Biosci 1998; 3: D1134D1147.
  • 47
    Bannasch P, Klimek F, Mayer D. Early bioenergetic changes in hepatocarcinogenesis: preneoplastic phenotypes mimic responses to insulin and thyroid hormone. J Bioenerg Biomembr 1997; 29: 303313.
  • 48
    Cadoret A, Ovejero C, Saadi-Kheddouci S, Souil E, Fabre M, Romagnolo B, Kahn A, et al. Hepatomegaly in transgenic mice expressing an oncogenic form of β-catenin. Cancer Res 2001; 61: 32453249.
  • 49
    Coghlan MP, Culbert AA, Cross DA, Corcoran SL, Ytaes JW, Pearce NJ, Rausch OL, et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 2000; 7: 793803.
  • 50
    Cross DA, Culbert AA, Chalmers KA, Facci L, Skaper SD, Reith AD. Selective small molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurons from death. J Neurochem 2001; 77: 94102.